血管の発生と新生-基礎と臨床

出版社： メディカルレビュー社
著者：
発行日： 2003-11-01
分野： 基礎医学  >  組織学/発生学
ISBN： 4896006453
電子書籍版： 2003-11-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,500 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,750 円(税込)

購入する

商品紹介

心・血管系の再生医学は、既に臨床試験に進んでおり、それが短期的あるいは長期的に疾患に及ぼす効果を検証する段階に入っている。これらの臨床経験が基礎科学を刺激する可能性が大いにある。再生医学がまっとうに発達できるために基礎の知見が進むことが肝心かなめである。

目次

  • 血管の発生と新生-基礎と臨床

    ―目次―

    １　血管性微小環境ー造血と血管新生の連関
    ２　血管安定性の誘導機構
    ３　組織特異的血管新生抑制因子
    ４　ＥＳ細胞（胚性幹細胞）からの血管形成
    ５　低酸素誘発性血管新生と疾患
    ６　血管の再生医療
    ７　血小板性VEGF増多症としてのCrow-Fukase症候群
    ８　心筋再生の展望
    ９　血管再生を利用した遺伝子治療
    10　動脈硬化のサイトカイン遺伝子治療
    11　血管新生制御による抗癌治療の開発
    12　AAVﾍﾞｸﾀｰを用いた抗腫瘍血管遺伝子療法
    13　末梢動脈疾患に対する骨髄単核球移植術
    14　血小板由来血管新生因子
    15　血管新生の虚血性疾患（循環器領域）への臨床応用に向けて
    16　内皮細胞の管腔形成におけるglycogen synyhase kinase-3βの役割

    外国語索引
    日本語索引

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 血管性微小環境-造血と血管新生の連関

P.9 掲載の参考文献
1) Master Z, Jones N, Tran J, et al:Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak. EMBO J 20:5919-5928, 2001
 
2) Trentin JJ:Influence of hematopoietic organ stroma (Hematopoietic Inductive Microenvironments) on stem cell differentiation. in Regulation of Hematopoiesis, ed by Gordon AS. New York, Appleton-Century-Crofts, 161-186, 1970
 
3) Jones PH, Watt FM:Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 73:713-724, 1993
PubMed
4) Takakura N, Huang X-L, Naruse T, et al:Critical role of the TIE2 endothelial receptor in the development of definitive hematopoiesis. Immunity 9:677-686, 1998
PubMed
5) Takakura N, Watanabe T, Suenobu S, et al:A role of hematopoietic stem cells in promoting angiogenesis. Cell 102:199-209, 2000
PubMed
6) Matsumoto K, Yoshitomi H, Rossant J, et al:Liver oragnogenesis promoted by endothelial cells prior to vascular function. Science 294:562-563, 2001
 
7) Lammert E, Cleaver O, Melton D:Induction of pancreatic differentiation by signals from blood vessels. Science 294:564-567, 2001
PubMed
8) Palmer TD, Willhoite A, Gage F:Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 425:479-494, 2000
PubMed
9) Gussoni E, Soneoka Y, Strickland CD, et al:Dystrophin expression in the, mdx mouse restored by stem cell transplantaion. Nature 401:390-394, 1999
 
10) Jiang Y, Jahagirdar BN, Reinhardt RL, et al:Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49, 2002
PubMed

2 血管安定性の誘導機構

P.17 掲載の参考文献
1) Hellstrom M, Kalen M, Lindahl P, et al:Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:3047-3055, 1999
PubMed
2) Lindahl P, Johansson BR, Leveen P, et al:Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277:242-245, 1997
PubMed
3) Suri C, Jones PF, Patan S, et al:Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180, 1996
PubMed
4) Takakura N, Huang XL, Naruse T, et al:Critical role of the TIE2 endothelial cell receptor in the development of definitive hematopoiesis. Immunity 9:677-686, 1998
PubMed
5) Maisonpierre PC, Suri C, Jones PF, et al:Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997
PubMed
6) Takakura N, Watanabe T, Suenobu S, et al:A role for hematopoietic stem cells in promoting angiogenesis. Cell 102:199-209, 2000
PubMed
7) Thurston G, Suri C, Smith K, et al:Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511-2514, 1999
PubMed

3 組織特異的血管新生抑制因子 -Chondromodulinとtenomodulin

P.28 掲載の参考文献
1) Eisenstein R, Sorgente N, Soble LW, et al:The resistance of certain tissues to invasion;Penetrability of explanted tissues by vascularized mesenchyme. Am J Pathol 73:765-774, 1973
PubMed
2) Sorgente N, Kuettner KE, Soble LW, et al:The resistance of certain tissues to invasion. II. Evidence for extractable factors in cartilage which inhibit invasion by vascularized mesenchyme. Lab Invest 32:217-222, 1975
PubMed
3) Moses MA, Sudhalter J, Langer R:Isolation and characterization of an inhibitor of neovascularization from scapupar chondrocytes. J Cell Biol 119:475-482, 1992
PubMed
4) Ohba Y, Goto Y, Kimura Y, et al:Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochim Biophys Acta 1245:1-8, 1995
PubMed
5) Hiraki Y, Inoue H, Iyama K, et al:Identification of chondromodulin-I as a novel endothelial cell growth inhibitor;Purification and its localization in the avascular zone of epiphyseal cartilage. J Biol Chem 272:32419-32426, 1997
PubMed
6) Hiraki Y, Tanaka H, Inoue H, et al:Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytes. Biochem Biophys Res Commun 175:971-977, 1991
PubMed
7) Hiraki Y, Mitsui K, Endo N, et al:Molecular cloning of human chondromodulin-I, a cartilage-derived growth modulating factor, and its expression in Chinese hamster ovary cells. Eur J Biochem 260:869-878, 1999
 
8) Shukunami C, Iyama K, Inoue H, et al:Spatiotemporal pattern of the mouse chondromodulin-I gene expression and its regulatory role in vascular invasion into cartilage during endochondral bone formation. Int J Dev Biol 43:39-49, 1999
PubMed
9) Azizan A, Holaday N, Neame PJ:Post-translational processing of bovine chondromodulin-I. J Biol Chem 276:23632-23638, 2001
 
10) Yanagihara I, Yamagata M, Sakai N, et al:Genomic organization of the human chondromodulin-1 gene containing a promoter region that confers the expression of reporter gene in chondrogenic ATDC 5 cells. J Bone Miner Res 15:421-429, 2000
 
11) Sachdev SW, Dietz UH, Oshima Y, et al:Sequence analysis of zebrafish chondromodulin-1 and expression profile in the notochord and chondrogenic regions during cartilage morphogenesis. Mech Dev 105:157-162, 2001
PubMed
12) Gerber HP, Vu TH, Ryan AM, et al:VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623-628, 1999
PubMed
13) Engsig MT, Chen QJ, Vu TH, et al:Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 151:879-890, 2000
 
14) Colnot CI, Helms JA:A molecular analysis of matrix remodeling and angiogenesis during long bone development. Mech Dev 100:245-250, 2001
PubMed
15) Takeda S, Bonnamy JP, Owen MJ, et al:Continuous expression of Cbfal in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfal-deficient mice. Genes Dev 15:467-481, 2001
 
16) Holmbeck K, Bianco P, Caterina J, et al:MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99:81-92, 1999
PubMed
17) Zhou Z, Apte SS, Soininen R, et al:Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A 97:4052-4057, 2000
PubMed
18) Vu TH, Shipley JM, Bergers G, et al:MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93:411-422, 1998
PubMed
19) Hayami T, Shukunami C, Mitsui K, et al:Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. FEBS Lett 458:436-440, 1999
PubMed
20) Shukunami C, Oshima Y, Hiraki Y:Molecular cloning of tenomodulin, a novel chondromodulin-I related gene. Biochem Biophys Res Commun 280:1323-1327, 2001
PubMed
21) Yamana K, Wada H, Takahashi Y, et al:Molecular cloning and characterization of chm1, a novel membrane molecule similar to chondromodulin-I. Biochem Biophys Res Commun 280:1101-1106, 2001
 
22) Oshima Y, Shukunami C, Honda J, et al:Expression and localization of tenomodulin, a transmembrane type chondromodulin-I related angiogesis inhibitor, in mouse eyes. Invest Ophthalmol Vis Sci 44:1814-1823, 2003
 
23) Funaki H, Sawaguchi S, Yaoeda K, et al:Expression and localization of angiogenic inhibitory factor, chondromodulin-I, in adult rat eye. Invest Ophthalmol Vis Sci 42:1193-1200, 2001
PubMed
24) Nakamichi Y, Shukunami C, Yamada T, et al:Chondromodulin I is a bone remodeling factor. Mol Cell Biol 23:636-644, 2003
PubMed
25) Mori Y, Hiraki Y, Shukunami C, et al:Stimulation of osteoblast proliferation by the cartilage-derived growth promoting factors chondromodulin-I and Is. FEBS Lett 406:310-314, 1997
PubMed

4 ES細胞(胚性幹細胞)からの血管形成

P.40 掲載の参考文献
1) Yamashita J, Itoh H, Hirashima M, et al:Flk 1-positive cells derived from embryonic stem cells serve as vascular progenitor. Nature 408:92-96, 2000
 
2) Risaw W:Mechanisms of angiogenesis. Nature 386:671-674, 1997
 
3) Pardanaud L, Luton D, Prigent M, et al:Two distinct endothelial lineages in ontogeny, one of them related to hemopoiesis. Development 122:1363-1371, 1996
PubMed
4) Yamaguchi TP, Dumont DJ, Conlon RA, et al:Flk-1, a flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development 118:489-498, 1993
PubMed
5) Shalaby F, Rossant J, Yamaguchi TP, et al:Failure of blood-island formation and vasculogenesis in Flk 1-deficient mice. Nature 376:62-66, 1995
PubMed
6) Hirashima M, Kataoka H, Nishikawa S, et al:Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood 93:1253-1263, 1999
 
7) Wang HU, Chen ZF, Anderson DJ:Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93:741-753, 1998
PubMed
8) Rajantie I, Ekman N, Iljin K, et al:Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol 21:4647-4655, 2001
 
9) Shutter JR, Scully S, Fan W, et al:D114, a novel Notch ligand expressed in arterial endothelium. Genes Dev 14:1313-1318, 2000
 
10) Zhong TP, Childs S, Leu JP, et al:Gridlock signalling pathway fashions the first embryonic artery. Nature 414:216-220, 2001
PubMed
11) Urness LD, Sorensen LK, Li DY:Arteriovenous malformations in mice lacking activin receptorlike kinase-1. Nat Genet 26:328-331, 2000
PubMed
12) Lawson ND, Scheer N, Pham VN, et al:Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 128:3675-3683, 2001
PubMed
13) Nakagawa O, McFadden DG, Nakagawa M, et al:Members of the HRT family of basic helixloop-helix proteins act as transcriptional repressors downstream of Notch signaling. Proc Natl Acad Sci U S A 97:13655-13660, 2000
 
14) Zhang XQ, Takakura N, Oike Y, et al:Stromal cells expressing ephrin-B2 promote the growth and sprouting of ephrin-B2+ endothelial cells. Blood 98:1028-1037, 2001
PubMed
15) Lawson ND, Vogel AM, Weinstein BM:Sonic hedgehog and vascular endothelial growth factor act upstream of the notch pathway during arterial endothelial differentiation. Dev Cell 3:127-136, 2002
PubMed
16) Liu ZJ, Shirakawa T, Li Y, et al:Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells;Implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23:14-25, 2003
PubMed
17) Mukouyama YS, Shin D, Britsch S, et al:Sensory nerves determine the pattern of arterial differentation and blood vessel branching in the skin. Cell 109:693-705, 2002
 
18) Skobe M, Hawighorst T, Jackson DG, et al:Induction of tumor lymphangiogenesis by VEGFC promotes breast cancer metastasis. Nat Med 7:192-198, 2001
PubMed
19) Makinen T, Jussila L, Veikkola T, et al:Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 7:199-205, 2001
PubMed
20) Wigle JT, Harvey N, Detmar M, et al:An essential role for Prox-1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 21:1505-1513, 2002
 
21) Banerji S, Ni J, Wang SX, et al:LYVE-1 a new homologue of the CD44 glycoprotein, is a lymphspecific receptor for hyaluronan. J Cell Biol 144:789-801, 1999
PubMed
22) Breiteneder-Geleff S, Soleiman A, Kowalski H, et al:Angiosarcomas express mixed endothelialphenotypes of blood and lymphatic capillaries;Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154:385-394, 1999
PubMed
23) Etchevers HC, Vincent C, Le Douarin NM, et al:The cephalic neural crest provides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. Development 128:1059-1068, 2001
PubMed
24) Mikawa T, Gourdie RG:Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with in growth of the epicardial organ. Dev Biol 174:221-232, 1996
 
25) Orlic D, Kajstura J, Chimenti S, et al:Bone marrow cells regenerate infarcted myocardium. Nature 410:701-705, 2001
PubMed
26) Sata M, Saiura A, Kunisato A, et al:Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 8:403-409, 2002
PubMed
27) Nishikawa SI, Nishikawa S, Hirashima M, et al:Progressive lineage analysis by celi sorting and culture identifies FLKr+VE-cadherin+ cells at a diverging point of endothelial and hemopoietic lineages. Development 125:1747-1757, 1998
 
28) Yurugi-Kobayashi T, Itoh H, Yamashita J, et al:Effective contribution of transplanted vascular progenitor cells derived from embryonic stem cells to adult neovascularization in proper differentiation stage, Blood 101:2675-2678, 2003
PubMed
29) Sone M, Itoh H, Yamashita J, et al:Different differentiation kinetics of vascular progenitor cells in primate and mouse embryonic stem cells. Circulation 107:2085-2088, 2003
PubMed
30) Gilbert SF:Lateral plate mesoderm and endoderm. in Developmental Biology (6th ed.), Sunderland, Massachusetts, SINAUER Associates, 482, 2000
 

5 低酸素誘発性血管新生と疾患

P.49 掲載の参考文献
1) Plate KH, Breier G, Weich HA, et al:Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359.:845-848, 1992
PubMed
2) Shweiki D, Itin A, Soffer D, et al:Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845, 1992
PubMed
3) Risau W:Mechanisms of angiogenesis. Nature 386:671-674, 1997
PubMed
4) Soker S, Takashima S, Miao HQ, et al:Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735-745, 1998
PubMed
5) Ferrara N:Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543, 1999
PubMed
6) Bates DO, Hillman NJ, Williams B, et al:Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 200:581-597, 2002
PubMed
7) Ikeda E, Achen MG, Breier G, et al:Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C 6 glioma cells. J Biol Chem 270:19761-19766, 1995
 
8) Levy NS, Chung S, Furneaux H, et al:Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273:6417-6423, 1998
 
9) Dibbens JA, Miller DL, Damert A, et al:Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell 10:907-919, 1999
PubMed
10) Damert A, Ikeda E, Risau W:Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C 6 glioma cells. Biochem J 327:419-423, 1997
 
11) Semenza GL:Hypoxia-inducible factor 1;Oxygen homeostasis and disease pathophysiology. Trends Mol Med 7:345-350, 2001
PubMed
12) Semenza GL:Hypoxia-inducible factor 1;Control of oxygen homeostasis in health and disease. Pediatr Res 49:614-617, 2001
PubMed
13) Semenza GL:HIF-1 and tumor progression;Pathophysiology and therapeutics. Trends Mol Med 8:S62-S67, 2002
PubMed
14) 依馬正次:bHLH-PAS型転写因子群の構造とその生理機能. 生化学 73:81-88, 2001
 
15) Ivan M, Haberberger T, Gervasi DC, et al:Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 99:13459-13464, 2002
PubMed
16) Pereira T, Zheng X, Ruas JL, et al:Identification of residues critical for regulation of protein stability and the transactivation function of the hypoxia-inducible factor-1a by the von Hippel-Lindau tyuor suppressor gene product. J Biol Chem 278:6816-6823, 2003
 
17) Lando D, Peet DJ, Whelan DA, et al:Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858-861, 2002
PubMed
18) Lando D, Peet DJ, Gorman JJ, et al:FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16:1466-1471, 2002
PubMed
19) Hewitson KS, McNeill LA, Riordan MV, et al:Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor inhibiting HIF (FIH) and is related to the cupin structural family. J Biol Chem 277:26351-26355, 2002
 
20) Zagzag D, Zhong H, Scalzitti JM, et al:Expression of hypoxia-inducible factor1a in brain tumors;Association with angiogenesis, invasion, and progression. Cancer 88:2606-2618, 2000
 
21) Birner P, Gatterbauer B, Oberhuber G, et al:Expression of hypoxia-inducible factor-1a in oligodend ogliomas;Its impact on prognosis and on neoangiogenesis. Cancer 92:165-171, 2001
 
22) Birner P, Schindl M, Obermair A, et al:Expression of hypoxia-inducible factor1a in epithehal ovarian tumors;Its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7:1661-1668, 2001
 
23) Bos R, Zhong H, Hanrahan CF, et al:Levels of hypoxia-inducible factor-1a during breast carcinogenesis. J Natl Cancer Inst 93:309-314, 2001
 
24) Pugh CW, Ratcliffe PJ:The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 13:83-89, 2003
 
25) Ishida S, Shinoda K, Kawashima S, et al:Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 41:1649-1656, 2000
PubMed
26) Poulaki V, Qin W, Joussen AM, et al:Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1a and VEGF. J Clin Invest 109:805-815, 2002
 
27) Oliver SJ, Cheng TP, Banquerigo ML, et al:Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin;Reduction of vascular endothelial growth factor (VEGF). Cell Immunol 166:196-206, 1995
PubMed
28) Hollander AP, Corke KP, Freemont AJ, et al:Expression of hypoxia-inducible factor1a by macrophages in the rheumatoid synovium;Implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 44:1540-1544, 2001
 
29) Ikeda M, Hosoda Y, Hirose S, et al:Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J Pathol 191:426-433, 2000
PubMed

6 血管の再生医療

P.58 掲載の参考文献
1) Folkman J, Klagsbrun M:Angiogenic factors. Science 235:442-447, 1987
PubMed
2) Isner JM, Pieczek A, Schainfeld R, et al:Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischemic limb. Lancet 348:370-374, 1996
PubMed
3) Losordo DW, Vale PR, Symes JF, et al:Gene therapy for myocardial angiogenesis;Initial clinical results with direct myocardial injection of phVEGFI65 as sole therapy for myocardial ischemia. Circulation 98:2800-2804, 1998
PubMed
4) Risau W, Sariola H, Zerwes HG, et al:Vasculogenesis and angiogenesis in embryonic stem cell-derived embryoid bodies. Development 102:471-478, 1988
PubMed
5) Flamme l, Risau W:Induction of vasculogenesis and hematopoiesis in vitro. Development 116:435-439, 1992
 
6) Asahara T, Murohara T, Sullivan A, et al:Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
PubMed
7) Isner JM, Asahara T:Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 103:1231-1236, 1999
PubMed
8) Asahara T, Masuda H, Takahashi T, et al:Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228, 1999
PubMed
9) Kalka C, Masuda H, Takahashi T, et al:Transplantation of ex-vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 97:3422-3427, 2000
PubMed
10) Kawamoto A, Gwon HC, Iwaguro H, et al:Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103:634-637, 2001
PubMed
11) Asahara T, Takahashi T, Masuda H, et al:VEGF contributes to post-natal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18:3964-3972, 1999
 
12) Takahashi T, Kalka C, Masuda H, et al:Ischemia-and cytokine-induced mobilization of bone marrow derived endothelial progenitor cells for neovascularization. Nat Med 4:434-438, 1999
PubMed
13) Iwaguro H, Yamaguchi J, Kalka C, et al:Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 105:732-738, 2002
PubMed
14) Murasawa S, Llevadot J, Silver M, et al:Constitutive human telomerase reverse transcriptase expression enhances regenerative properties of endothelial progenitor cells. Circulation 106:1133-1139, 2002
PubMed
15) Murohara T, Ikeda H, Dvan J, et al:Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 105:1527-1536, 2000
 

7 血小板性VEGF増多症としてのCrow-Fukase症候群

P.66 掲載の参考文献
1) Watanabe O, Arimura K, Kitajima I, et al:Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347:702, 1996
PubMed
2) Nakanishi T, Sobue I, Toyokura Y, et al:The Crow-Fukase syndrome;A study of 102 cases in Japan. Neurology 34:712, 1984
PubMed
3) Lesprit P, Authier FJ, Gherardi R, et al:Acute arterial obliteration;A new feature of the POEMS syndrome? Medicine 75:226, 1996
PubMed
4) Blum S, Issbruker K, Willuweit A, et al:An inhibitory role of the phosphatidylinositol 3-kinase-signaling Pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem 276:33428-33434, 2001
PubMed
5) Hashiguchi T, Arimura K, Matsumuro K, et al:Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. Muscle Nerve 23:1051, 2000
PubMed
6) Niimi H, Arimura K, Jonosono M, et al:VEGF is causative for pulmonary hypertension in a patient with Crow-Fukase (POEMS) syndrome. Intern Med 39:1101-1104, 2000
 
7) Michizono K, Umehara F, Hashiguchi T, et al:Circulating levels of MMP-1,-2,-3,-9, and TIMP-1 are increased in POEMS syndrome. Neurology 56:807-810, 2001
PubMed
8) Sawicki G, Salas E, Murat J, et al:Release of gelatinase A during platelet activation mediates aggregation. Nature 386:616-619, 1997
PubMed

8 心筋再生の展望

P.75 掲載の参考文献
1) Roy NS, Wang S, Jiang L, et al:In vitro neurogenesis by progenitor cells isolated from the adult human hippocampus. Nat Med 6:271-277, 2000
 
2) Prockop DJ:Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74, 1997
PubMed
3) Pittenger MF, Mackay AM, Beck SC, et al:Multilineage potential of adult human mesenchymal stem cells;Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147, 1999
PubMed
4) Barry FP, Boynton RE, Haynesworth S, et al:The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun 265:134-139, 1999
PubMed
5) van den Bos C, Mosca JD, Winkles J, et al:Human mesenchymal stem cells respond to fibroblast growth factors. Hum Cell 10:45-50, 1997
PubMed
6) Makino S, Fukuda K, Miyoshi S, et al:Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103:697-705, 1999
PubMed
7) Doetschman TC, Eistetter H, Katz M, et al:The in vitro development of blastocyst-derived embryonic stem cell lines;Formation of visceral yolk sac, blood islands and myocardium. J Embryol Exp Morphol 87:27-45, 1985
PubMed
8) Dorfman J, Duong M, Zibaitis A, et al:Myocardial tissue engineering with autologous myoblast implantation. J Thorac Cardiovasc Surg 116:744-751, 1998
PubMed
9) Murry CE, Wiseman RW, Schwartz SM, et al:Skeletal myoblast transplantation for repair of myocardial necrosis. J Clin Invest 98:2512-2523, 1996
PubMed
10) Taylor DA, Atkins BZ, Hungspreugs P, et al:Regenerating functional myocardium;Improved performance after skeletal myoblast transplantation. Nat Med 4:929-933, 1998
PubMed
11) Leor J, Patterson M, Quinones MJ, et al:Transplantation of fetal myocardial tissue into the infarcted myocardium of rat. A potential method for repair of infarcted myocardium? Circulation 94 (Suppl.):II332-II336, 1996
 
12) Li RK, Mickle DA, Weisel RD, et al:Natural history of fetal rat cardiomyocytes transplanted into adult rat myocardial scar tissue. Circulation 96 (Suppl.):II179-II186, discussion 186-187, 1997
 
13) Tomita S, Li RK, Weisel RD, et al:Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100 (Suppl.):II247-II256, 1999
 
14) Takahashi T, Kalka C, Masuda H, et al:Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434-438, 1999
PubMed

9 血管再生を利用した遺伝子治療

P.84 掲載の参考文献
1) Schratzberger P, Walter DH, Rittig K, et al:Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 107:1083-1092, 2001
PubMed

10 動脈硬化のサイトカイン遺伝子治療

P.92 掲載の参考文献
1) Gupta S, Pablo AM, Jiang X, et al:IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 99:2752-2761, 1997
PubMed
2) Whitman SC, Ravisankar P, Elam H, et al:Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/-mice. Am J Pathol 157:1819-1824, 2000
PubMed
3) Devlin CM, Kuriakose G, Hirsch E, et al:Genetic alterations of IL-1 receptor antagonist in mice cholesterol level and foam cell lesion size. Proc Natl Acad Sci U S A 99:6280-6285, 2002
PubMed
4) Seino Y, Ikeda U, Ikeda M, et al:Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 6:87-91, 1994
PubMed
5) Huber SA, Sakkinen P, Conze D, et al:Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol I9:2364-2367, 1999
 
6) Lee TS, Yen HC, Pan CC, et al:The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19:734-742, 1999
 
7) Whitman SC, Ravisankar P, Daugherty A:Interleukin-18 enhances atherosclerosis in apolipoprotein E (-/-) mice through release of interferon-gamma. Circ Res 90:E34-E38, 2002
PubMed
8) Mallat Z, Corbaz A, Scoazec A, et al:Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 89:E41-E45, 2001
PubMed
9) Gu L, Okada Y, Clinton SK, et al:Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2:275-281, 1998
PubMed
10) Boring L, Gosling J, Cleary M, et al:Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-897, 1998
PubMed
11) Zimmerman MA, Selzman CH, Reznikov LL, et al:Interleukin-11 attenuates human vascular smooth muscle cell proliferation. Am J Physiol Heart Circ Physiol 283:H175-H180, 2002
PubMed
12) Mahboubi K, Biedermann BC, Carroll JM, et al:IL-11 activates human endothelial cells to resist immune-mediated injury. J Immunol 164:3837-3846, 2000
PubMed
13) Vadiveloo PK, Stanton HR, Cochran FW, et al:Interleukin-4 inhibits human smooth muscle cell proliferation. Artery 21:161-181, 1994
PubMed
14) George J, Shoenfeld Y, Gilburd B, et al:Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis. Circ Res 86:1203-1210, 2000
PubMed
15) Donnelly RP, Dickensheets H, Finbloom DS:The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 19:563-573, 1999
 
16) Berg DJ, Kuhn R, Rajewsky K, et al:Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 96:2339-2347, 1995
 
17) Wang P, Wu P, Siegel MI, et al:Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270:9558-9563, 1995
 
18) Lee TS, Chau LY:Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8:240-246, 2002
PubMed
19) Mallat Z, Heymes C, Ohan J, et al:Expression of interleukin-10 in advanced human atherosclerotic plaques;Relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 19:611-616, 1999
 
20) Mallat Z, Besnard S, Duriez M, et al:Protective role of interleukin-10 in atherosclerosis. Circ Res 85:E17-E24, 1999
PubMed
21) Pinderski LJ, Fischbein MP, Subbanagounder G, et al:Overexpression of interleukin-10 by activated T atherosclerosis in LDL receptor-deficient Mice by macrophage phenotypes. Circ Res 90:1064-1071, 2002
PubMed
22) Von Der Thusen JH, Kuiper J, Fekkes ML, et al:Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/-mice. FASEB J 15:2730-2732, 2001
PubMed
23) van Exel E, Gussekloo J, de Craen AJ, et al:Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes;The Leiden 85-Plus study. Diabetes 51:1088-1092, 2002
PubMed
24) Pasceri V, Yeh ET:A tale of two diseases;Atherosclcrosis and rheumatoid arthritis. Circulation 100:2124-2126, 1999
PubMed
25) Hurlimann D, Forster A, Noll G, et al:Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184-2187, 2002
PubMed
26) Schreyer SA, Peschon JJ, LeBoeuf RC:Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem 271:26174-26178, 1996
PubMed
27) Smith JD, Trogan E, Ginsberg M, et al:Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A 92:8264-8268, 1995
PubMed
28) Pinderski Oslund LJ, Hedrick CC, Olvera T, et al:Interleukin-10 blocks atherosclerotic events in vitro. Arterioscler Thromb Vasc Biol 19:2847-2853, 1999
 

11 血管新生制御による抗癌治療法の開発 -可溶型血管新生因子受容体を用いた癌の遺伝子治療

P.100 掲載の参考文献
1) Takayama K, Ueno H, Nakanishi Y, et al:Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 60:2169-2177, 2000
PubMed
2) Honda M, Sakamoto T, Ishibashi T, et al:Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection;A role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 7:978-985, 2000
PubMed
3) Shiose S, Sakamoto T, Yoshikawa H, et al:Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma. Invest Ophthalmol Vis Sci 41:2395-2403, 2000
PubMed
4) Oshima Y, Sakamoto T, Hisatomi T, et al:Gene transfer of soluble TGF-B type II receptor inhibits experimental proliferative vitreoretinopathy. Gene Ther 9:1214-1220, 2002
PubMed
5) Hisatomi T, Sakamoto T, Yamanaka I, et al:Photocoagulation-induced retinal gliosis is inhibited by systemically expressed soluble TGF-B receptor type II via adenovirus mediated gene transfer. Lab Invest 82:863-870, 2002
PubMed
6) Ogawa T, Takayama K, Takakura N, et al:Anti-tumor angiogenesis therapy using soluble receptors Enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 9:633-640, 2002
PubMed
7) Millauer B, Shawver LK, Plate KH, et al:Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579, 1994
PubMed
8) Presta LG, Chen H, 0'Connor SJ, et al:Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997
 
9) Fong TA, Shawver LK, Sun L, et al:SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106, 1999
PubMed
10) Laird AD, Vajkoczy P, Shawver LK, et al:SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160, 2000
PubMed
11) Kendall RL, Thomas KA:Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A 90:10705-10709, 1993
PubMed

12 AAVベクターを用いた抗腫瘍血管遺伝子療法

P.107 掲載の参考文献
1) Khuri FR, Nemunaitis J, Ganly I, et al:A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:879-885, 2000
PubMed
2) Simons JW, Mikhak B, Chang JF, et al:Induction of immunity to prostate cancer antigens;Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor using ex vivo gene transfer. Cancer Res 59:5160-5168, 1999
PubMed
3) Abonour R, Williams DA, Einhorn L, et al:Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 6:652-658, 2001
 
4) Bonini C, Ferrari G, Verzeletti S, et al:HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719-1724, 1997
PubMed
5) Shi W, Teschendorf C, Muzyczka N, et al:Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther 9:513-521, 2002
PubMed
6) Kuo CJ, Farnebo F, Mulligan RC, et al:Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 98:4605-4610, 2001
PubMed
7) Ma HI, Guo P, Li J, et al:Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res 62:756-763, 2002
PubMed
8) Hasumi Y, Mizukami H, Urabe M, et al:Soluble Flt-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 62:2019-2023, 2002
PubMed
9) Kohno T, Mizukami H, Suzuki M, et al:Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63:5091-5094, 2003
PubMed
10) Saga Y, Mizukami H, Suzuki M, et al:Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther 8:1450-1455, 2001
PubMed
11) Boehm T, Folkman J, Browder T, et al:Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997
 
12) Russell DW, Kay MA:Adeno-associated virus vectors and hematology. Blood 94:864-874, 1999
PubMed
13) Surosky RT, Urabe M, Godwin SG, et al:Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol 71:7951-7959, 1997
PubMed
14) Davidson BL, Stein CS, Heth JA, et al:Recombinant adeno-associated virus type 2, 4, and 5 vectors;Transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 97:3428-3432, 2000
PubMed
15) Chao H, Liu Y, Rabinowitz J, et al:Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2:619-623, 2000
PubMed
16) Rabinowitz JE, Rolling F, Li C, et al:Cross-packaging of a single adeno associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76:791-801, 2002
PubMed
17) Gao GP, Alvira MR, Wang L, et al:Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99:11854-11859, 2002
PubMed
18) Kanazawa T, Mizukami H, Okada T, et al:Suicide gene therapy using AAV-HSVtk/ganciclovirin combination with irradiation results in regression of human head and neck cancer xenografts in nude mice. Gene Ther 10:51-58, 2003
PubMed

13 末梢動脈疾患に対する骨髄単核球移植術-血中血管新生因子の変化

P.118 掲載の参考文献
1) Baumgartner I, Pieczek A, Manor O, et al:Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114-1123, 1998
PubMed
2) Losordo DW, Vale PR, Symes JF, et al:Gene therapy for myocardial angiogenesis;Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800-2804, 1998
PubMed
3) Asahara T, Murohara T, Sullivan A, et al:Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
PubMed
4) Crosby JR, Kaminski WE, Schatteman G, et al:Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ Res 87:728-730, 2000
PubMed
5) Tateishi-Yuyama E, Matsubara H, Murohara T, et al:Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells;A pilot study and a randomised controlled trial. Lancet 360:427-435, 2002
 

14 血小板由来血管新生因子

P.128 掲載の参考文献
1) 渋谷正史:血管新生にかかわる多様なシグナル伝達系. 実験医20:1076-1083, 2002
 
2) Murata T, Ushikubi F, Matsuoka T, et al:Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388:678-682, 1997
PubMed
3) Enjyoji K, Sevigny J, Lin Y, et al:Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5:1010-1017, 1999
PubMed
4) Pipili-Synetos E, Papadimitriou E, Maragoudakis ME:Evidence that platelets promote tube formation by endothelial cells on matrigel. Br J Pharmacol 125:1252-1257, 1998
PubMed
5) Folkman J:Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31, 1995
PubMed
6) Pinedo HM, Verheul HM, D'Amato RJ, et al:Involvement of platelets in tumour angiogenesis? Lancet 352:1775-1777, 1998
PubMed
7) Frenette PS, Johnson RC, Hynes RO, et al:Platelets roll on stimulated endothelium in vivo;An interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A 92:7450-7454, 1995
PubMed
8) Henn V, Slupsky JR, Grafe M, et al:CD40 Ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591-594, 1998
PubMed
9) 渋谷正史:血管内皮増殖因子 VEGFの作用機構. 実験医20:1103-1109, 2002
 
10) Mohle R, Green D, Moore MA, et al:Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 94:663-668, 1997
PubMed
11) Pintucci G, Froum S, Pinnell J, et al:Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost 88:834-842, 2002
PubMed
12) 有村公良, 橋川照人, 納 光弘:Crow-Fukase症候群の発症機序とVEGF. 臨神経41:1144-1146, 2001
 
13) 高倉伸幸:アンジオポエチン. 実験医20:1110-1115, 2002
 
14) Huang YQ, Li JJ, Karpatkin S:Identification of a family of alternatively spliced mRNA species of angiopoietin-1. Blood 95:1993-1999, 2000
PubMed
15) Li JJ, Huang YQ, Basch R, et al:Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost 85:204-206, 2001
PubMed
16) Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al:Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 97:441-448, 1997
PubMed
17) Ishikawa F, Miyazono K, Hellman U, et al:Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557-562, 1989
PubMed
18) Miyadera K, Sumizawa T, Haraguchi M, et al:Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factorl/thymidine phosphorylase. Cancer Res 55:1687-1690, 1995
 
19) Matsushita S, Nitanda T, Furukawa T, et al:The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res 59:1911-1916, 1999
PubMed
20) 別所一彦, 中村敏一:HGFによる血管新生. 実験医20:1124-1132, 2002
 
21) Nakamura T, Nishizawa T, Hagiya M, et al:Molecular cloning and expression of human hepatocyte growth factor. Nature 342:440-443, 1989
PubMed
22) 鈴木裕之, 宮園浩平:TGF-B シグナル伝達と疾患. 実験医21:184-189, 2003
 
23) Grainger DJ, Wakefield L, Bethell HW, et al:Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med 1:932-937, 1995
PubMed
24) Yatomi Y, Ozaki Y, Ohmori T, et al:Sphingosine 1-phosphate;Synthesis and release. Prostaglandins Other Lipid Mediat 64:107-122, 2001
PubMed
25) 矢冨 裕:血小板由来生理活性脂質スフィンゴシン 1-リン酸の研究の新展開. 日血栓止血会誌 13:237-244, 2002
 
26) Hisano N, Yatomi Y, Satoh K, et al:Induction and suppression of endothelial cell apoptosis by sphingolipids;A possible in vitro model for cell-cell interactions between platelets and endothelial cells. Blood 93:4293-4299, 1999
PubMed
27) Lee MJ, Thangada S, Claffey KP, et al:Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 99:301-312, 1999
PubMed
28) Wang F, Van Brocklyn JR, Hobson Jp, et al:Sphingosine 1-phosphate stimulates cell migration through a Gi-coupled cell surface receptor. Potential involvement in angiogenesis. J Biol Chem 274:35343-35350, 1999
PubMed
29) Garcia JG, Liu F, Verin AD, et al:Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 108:689-701, 2001
PubMed
30) Jimenez B, Volpert OV, Crawford SE, et al:Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6:41-48, 2000
PubMed
31) Abdelouahed M, Ludlow A, Brunner G, et al:Activation of platelet-transforming growth factor beta-1 in the absence of thrombospondin-1. J Biol Chem 275:17933-17936, 2000
PubMed
32) Brandt E, Petersen F, Ludwig A, et al:The beta-thromboglobulins and platelet factor 4;Blood platelet-derived CXC chemokines with divergent roles in early neutrophil regulation. J Leukoc Biol 67:471-478, 2000
PubMed
33) Maione TE, Gray GS, Petro J, et al:Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77-79, 1990
PubMed

15 血管新生の虚血性疾患(循環器領域)への臨床応用に向けて

P.138 掲載の参考文献
1) Takeshita S, Zheng LP, Brogi E, et al:Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93:662-670, 1994
 
2) Takeshita S, Pu LQ, Stein LA, et al:Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 90 (Pt. 2):II228-II234, 1994
 
3) Losordo DW, Vale PR, Symes JF, et al:Gene therapy for myocardial angiogenesis;Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800-2804, 1998
PubMed
4) Rosengart TK, Lee LY, Patel SR, et al:Angiogenesis gene therapy;Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100:468-474, 1999
PubMed
5) Grines CL, Watkins MW, Helmer G, et al:Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105:1291-1297, 2002
PubMed
6) Hedman M, Hartikainen J, Syvanne M, et al:Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia;Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107:2677-2683, 2003
PubMed
7) Asahara T, Murohara T, Sullivan A, et al:Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
PubMed
8) Kalka C, Masuda H, Takahashi T, et al:Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 97:3422-3427, 2000
PubMed
9) Tateishi-Yuyama E, Matsubara H, Murohara T, et al, Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators:Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells. A pilot study and a randomised controlled trial. Lancet 360:427-435, 2002
 
10) Makino S, Fukuda K, Miyoshi S, et al:Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103:697-705, 1999
PubMed
11) Tomita S, Li RK, Weisel RD, et al:Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 100 (Suppl.):II 247-II 256, 1999
 
12) Orlic D, Kajstura J, Chimenti S, et al:Bone marrow cells regenerate infarcted myocardium. Nature 410:701-705, 2001
PubMed
13) Hamano K, Nishida M, Hirata K, et al:Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease;Clinical trial and preliminary results. Jpn Circ J 65:845-847, 2001
PubMed
14) Matsubara H, Kamihata H, Nishiue T, et al:Mechanisms and therapeutic strategy for cardiac remodeling;Therapeutic myo-angiogenesis for ischemia-induced myocardial remodeling by transplantation of autologous bone marrow mononuclear cells. Jpn Circ J 67 (Suppl.I):12, 2003
 
15) Strauer BE, Brehm M, Zeus T, et al:Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106:1913-1918, 2002
PubMed
16) Assmus B, Schachinger V, Teupe C, et al:Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106:3009-3017, 2002
PubMed
17) Stamm C, Westphal B, Kleine HD, et al:Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361:45-46, 2003
PubMed
18) Tse HF, Kwong YL, Chan JK, et al:Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361:47-49, 2003
PubMed
19) Orlic D, Kajstura J, Chimenti S, et al:Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 98:10344-10349, 2001
PubMed
20) Takahashi T, Kalka C, Masuda H, et al:Ischemia-and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434-438, 1999
PubMed
21) Yokoyama S, Li Y, Fukuda N, et al:New strategy of bone marrow implantation therapy for myocardial infarction (Porcine Study). Jpn Circ J 67 (Suppl.I):357, 2003
 
22) Yokoyama S, Li Y, Fukuda N, et al:Efficiency of bone marrow cell mobilization by granulocytecolony stimulating factor (GCSF) for acute myocardial infarction in Porcine. Jpn Circ J 67 (Suppl.I):502, 2003
 

16 内皮細胞の管腔形成におけるgtycogen synthase kinase-3βの役割

P.146 掲載の参考文献
1) Risau W:Mechanisms of angiogenesis. Nature 386:671-674, 1997
PubMed
2) Carmeliet P, Jain RK:Angiogenesis in cancer and other diseases. Nature 407:249-257, 2000
PubMed
3) Nelson AR, Fingleton B, Rothenberg ML, et al:Matrix metalloproteinases;Biologic activity and clinical implications. J Clin Oncol 18:1135-1149, 2000
PubMed
4) Gale NW, Yancopoulos GD:Growth factors acting via endothelial cell-specific receptor tyrosine kinases;VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13:1055-1066, 1999
PubMed
5) Suri C, Jones PF, Patan S, et al:Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-1180, 1996
PubMed
6) Bazzoni G, Dejana E, Lampugnani MG:Endothelial adhesion molecules in the development of the vascular tree;The garden of forking paths. Curr Opin Cell Biol 11:573-581, 1999
PubMed
7) Rupp PA, Little CD:Integrins in vascular development. Circ Res 89:566-572, 2001
PubMed
8) Brooks PC, Clark RA, Cheresh DA:Requirement of vascular integrin av B 3 for angiogenesis. Science 264:569-571, 1994
 
9) Vittet D, Buchou T, Schweitzer A, et al:Targeted null-mutation in the vascular endothelialcadherin gene impairs the organization of vascular-like structures in embryoid bodies. Proc Natl Acad Sci U S A 94:6273-6278, 1997
PubMed
10) Carmeliet P, Lampugnani MG, Moons L, et al:Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98:147-157, 1999
PubMed
11) Zimrin AB, Pepper MS, McMahon GA, et al:An antisense oligonucleotide to the notch ligand jagged enhances fibroblast growth factor-induced angiogenesis in vitro. J Biol Chem 271:32499-32502, 1996
 
12) Wang HU, Chen ZF, Anderson DJ:Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93:741-753, 1998
PubMed
13) Adams RH, Wilkinson GA, Weiss C, et al:Roles of ephrinB ligands and EphB receptors in cardiovascular development;Demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13:295-306, 1999
PubMed
14) Lindahl P, Hellstrom M, Kalen M, et al:Endothelial-perivascular cell signaling in vascular development;Lessons from knockout mice. Curr Opin Lipidol 9:407-411, 1998
PubMed
15) Montesano R, Orci L:Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 42:469-477, 1985
PubMed
16) Pepper MS, Ferrara N, Orci L, et al:Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824-831, 1992
PubMed
17) Nicosia RF, Ottinetti A:Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta;A comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 26:119-128, 1990
PubMed
18) Woodgett JR:Judging a protein by more than its name;GSK-3. Sci STKE 100:RE12, 2001
PubMed
19) Hoeflich KP, Luo J, Rubie EA, et al:Requirement for glycogen synthase kinase-3 B in cell survival and NF-xB activation. Nature 406:86-90, 2000
 
20) Harwood AJ:Regulation of GSK-3;Acellular multiprocessor. Cell 105:821-824, 2001
 
21) Pap M, Cooper GM:Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway, J Biol Chem 273:19929-19932, 1998
PubMed

書評

最近チェックした商品履歴

Loading...